After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
SOURCE PTC Therapeutics, Inc.
European regulators have delayed PTC Therapeutics' request for permanent approval of its Duchenne muscular dystrophy drug Translarna.
Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a strong on high relative volume candidate
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a "dead cat bounce" (down big yesterday but up big today) candidate
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.